Publications

Publications

Fleming TR and Harrington DP. Counting Processes and Survival Analysis. New York: John Wiley and Sons, 1991.

Harrington DP. The aftermath of falsified data in breast cancer trials. Chance 1997; 10:6-8.

Troxel AB, Harrington DP, and Lipsitz SR. Analysis of longitudinal data with non-ignorable non-monotone missing values. Applied Statistics 1998; 47:425-438.

Troxel AB, Lipsitz SR, and Harrington DP. Marginal models for the analysis of longitudinal measurements with nonignorable non-monotone missing data. Biometrika 1998; 85:661-672.

Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, Willman C, Hurd DD, Bennett JM, Blume KG, Head DR, Wiernik PH. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. New England Journal of Medicine 1998; 339:1649-1656.

Harrington DP. The randomized clinical trial. Journal of the American Statistical Association 2000; 95(449): 312-315.

Bernardo MVP, Harrington DP. Sample size calculations for the two-sample problem using the multiplicative intensity model. Stat Med, 2001; 20: 557-579.

Xu R, Harrington DP. A semiparametric estimate of treatment effects with censored data. Biometrics, 2001; 57: 875-885.

Chen M-H, Harrington DP, Ibrahim JG. Bayesian cure rate models for malignant melanoma: a case-study of Eastern Cooperative Oncology Group Trial E1690. Appl Statist 2002; 51(2):135-150.

Huang J, Harrington D. Penalized partial likelihood regression for right-censored data with bootstrap selection of the penalty parameter. Biometrics 2002; 58:781-791.

The International Myeloma Working Group (D. Harrington-participant).  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Working Group.  Br J Haematol 2003;121:749-757.

Joffe S, Harrington DP, George SL, Emanuel EJ, Budzinski LA, Weeks JC. Satisfaction of the uncertainty principle in cancer clinical trials: retrospective cohort analysis. BMJ 2004;328(7454):1463.

Huang J, Harrington D.  Dimension reduction in the linear model for right-censored data: predicting the change in HIV-1 RNA levels using clinical and protease gene mutation data.  Lifetime Data Anal 2004;10(4):425-443.

Ayanian J, et al.  Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium.  J Clin Oncol 2004;22(15):2992-2996.

Huang J, Harrington DP.  Iterative partial least squares with right-censored data analysis: a comparison to other dimension reduction techniques.  Biometrics 2005;61(1):17-24.

LaFramboise T, Weir BA, Zhao X, Beroukhim R, Li C, Harrington D, Sellers WR, Meyerson M.  Allele-specific amplification in cancer revealed by SNP array analysis.  PLoS Comput Biol 2005;1(6):e65.

Colla J, Buka S, Harrington D, Murphy JM.  Depression and modernization: a cross-cultural study of women.  Soc Psychiatry Psychiatr Epidemiol 2006;41(4):271-279.

Jiang H, Harrington D, Raby BA, Bertram L, Blacker D, Weiss ST, Lange C.  Family-based association test for time-to-onset data with time-dependent differences between the hazard functions.  Genet Epidemiol 2006;30:124-132.

Malin JL, Ko C, Ayanian JZ, Harrington D, Nerenz DR, Kahn KL, Ganther-Urmie J, Catalano PJ, Zaslavsky AM, Wallace RB, Guadagnoli E, Arora NK, Roudier MD, Ganz PA. Understanding cancer patients’ experience and outcomes: development and pilot study of the Cancer Care Outcomes Research and Surveillance patient survey.  Support Care Cancer 2006;14(8):837-848.

Laframboise T, Harrington D, Weir BA.  PLASQ: a generalized linear model-based procedure to determine allelic dosage in cancer cells from SNP array data.  Biostatistics 2007;2:323-336.